Russell Investments Group Ltd. Has $1.14 Million Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Russell Investments Group Ltd. increased its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) by 15.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,583 shares of the biotechnology company’s stock after purchasing an additional 3,259 shares during the period. Russell Investments Group Ltd. owned approximately 0.12% of Enanta Pharmaceuticals worth $1,144,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Captrust Financial Advisors raised its holdings in shares of Enanta Pharmaceuticals by 343.8% in the 1st quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company’s stock worth $61,000 after buying an additional 660 shares in the last quarter. Point72 Hong Kong Ltd grew its position in Enanta Pharmaceuticals by 83.7% in the second quarter. Point72 Hong Kong Ltd now owns 1,565 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 713 shares during the period. Quantbot Technologies LP grew its position in Enanta Pharmaceuticals by 13,411.8% in the second quarter. Quantbot Technologies LP now owns 2,297 shares of the biotechnology company’s stock valued at $108,000 after acquiring an additional 2,280 shares during the period. Mutual of America Capital Management LLC grew its position in Enanta Pharmaceuticals by 25.2% in the third quarter. Mutual of America Capital Management LLC now owns 3,875 shares of the biotechnology company’s stock valued at $201,000 after acquiring an additional 780 shares during the period. Finally, Teachers Retirement System of The State of Kentucky bought a new stake in Enanta Pharmaceuticals in the third quarter valued at $225,000. Institutional investors own 93.68% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on ENTA shares. JMP Securities lowered their price target on Enanta Pharmaceuticals from $82.00 to $65.00 in a research report on Tuesday, May 9th. SVB Leerink reiterated a “market perform” rating and issued a $49.00 price target on shares of Enanta Pharmaceuticals in a research report on Thursday, February 9th. JPMorgan Chase & Co. decreased their target price on Enanta Pharmaceuticals from $74.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 8th. Piper Sandler restated an “overweight” rating and set a $87.00 target price on shares of Enanta Pharmaceuticals in a report on Wednesday, February 8th. Finally, StockNews.com began coverage on Enanta Pharmaceuticals in a report on Thursday, May 18th. They set a “hold” rating on the stock. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $56.75.

Enanta Pharmaceuticals Stock Down 5.9 %

Enanta Pharmaceuticals stock opened at $25.41 on Thursday. The business’s 50-day simple moving average is $35.16 and its 200 day simple moving average is $43.10. The stock has a market cap of $535.13 million, a price-to-earnings ratio of -4.25 and a beta of 0.38. Enanta Pharmaceuticals, Inc. has a 12-month low of $23.03 and a 12-month high of $76.36.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) last posted its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($1.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.91) by $0.12. Enanta Pharmaceuticals had a negative return on equity of 40.56% and a negative net margin of 153.61%. The business had revenue of $17.80 million for the quarter, compared to analysts’ expectations of $19.06 million. During the same quarter last year, the business earned ($1.63) earnings per share. The firm’s quarterly revenue was down 4.9% compared to the same quarter last year. As a group, sell-side analysts expect that Enanta Pharmaceuticals, Inc. will post -6.34 EPS for the current year.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 27,912 shares of the stock in a transaction dated Monday, March 13th. The stock was sold at an average price of $45.16, for a total value of $1,260,505.92. Following the transaction, the chief executive officer now owns 819,810 shares of the company’s stock, valued at $37,022,619.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CFO Paul J. Mellett sold 10,440 shares of the firm’s stock in a transaction dated Wednesday, March 15th. The stock was sold at an average price of $44.43, for a total transaction of $463,849.20. Following the sale, the chief financial officer now owns 97,556 shares of the company’s stock, valued at $4,334,413.08. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Jay R. Luly sold 27,912 shares of the firm’s stock in a transaction dated Monday, March 13th. The stock was sold at an average price of $45.16, for a total value of $1,260,505.92. Following the sale, the chief executive officer now directly owns 819,810 shares in the company, valued at approximately $37,022,619.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 52,277 shares of company stock valued at $2,343,321. 12.70% of the stock is currently owned by company insiders.

Enanta Pharmaceuticals Company Profile

(Get Rating)

Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.